Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 28;10(1):350.
doi: 10.1186/s13104-017-2687-5.

Characterizing expanded access and compassionate use programs for experimental drugs

Jennifer E Miller  1   2 , Joseph S Ross  3   4   5 , Kenneth I Moch  6 , Arthur L Caplan  7
Affiliations

Characterizing expanded access and compassionate use programs for experimental drugs

Jennifer E Miller et al. BMC Res Notes. .

Abstract

Objective: We sought to determine the characteristics of "expanded access" and "compassionate use" programs registered in ClinicalTrials.gov and to determine the percentage of drugs provided through these programs that ultimately received FDA marketing approval.

Results: We identified 398 expanded access and compassionate use programs (hereafter referred to as expanded access programs) registered on ClinicalTrials.gov. Industry funded 61% (n = 241) of programs individually or collaboratively, while NIH and the US Federal Government rarely funded programs (3% [n = 11] and 2% [n = 6], respectively). Most programs provided access to drugs (71% [n = 282]), 11% to biologics (n = 43), and 10% to medical devices (n = 40). These programs covered 460 unique conditions, the most common being HIV (n = 26), leukemia (22), and multiple myeloma (n = 14). Only 2% of programs reported results in ClinicalTrials.gov. Most programs (82%) were open to enrolling adults and seniors (n = 326). These programs provided access to 210 unique experimental drugs, of which 76% have received FDA approval.

Keywords: 21st Century Cures Act; Access to medicines; Bioethics; Compassionate use; Ethics; Expanded access; Experimental drugs; Pharmaceutical industry; Policy; Real-world evidence; Right to Try Laws.

PubMed Disclaimer

References

    1. White House. Readout of the vice president’s meeting with right to try advocates. https://www.whitehouse.gov/the-press-office/2017/02/07/readout-vice-pres.... Accessed 15 Feb 2017.
    1. U.S. Food and Drug Administration. Expanded access INDs and protocols 2009–2015. http://www.fda.gov/NewsEvents/PublicHealthFocus/ExpandedAccessCompassion.... Accessed 15 Feb 2017.
    1. U.S. Food and Drug Administration. Expanded access (compassionate use) https://www.fda.gov/NewsEvents/PublicHealthFocus/ExpandedAccessCompassio.... Accessed 23 June 2017.
    1. U.S. Food and Drug Administration. Charging for investigational drugs under an IND—questions and answers, guidance for industry. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformat... Accessed 23 June 2017.
    1. Jarow JP, Lurie P, Ikenberry SC, Lemery S. Overview of FDA’s expanded access program for investigational drugs. Ther Innov Regul Sci. 2017;51(2):177–179. doi: 10.1177/2168479017694850. - DOI - PMC - PubMed

MeSH terms

Substances